Alcohol Use Disorder Treatment Companies

Request Free Sample Copy

Report ID: 3804
Published Date: May 12, 2025
Report Format: PDF, PPT

Buy Now

Companies Dominating the Alcohol Use Disorder Treatment Landscape

One of the key strategies adopted by the companies involved in the alcohol use disorder treatment market is investing in new drug formulations. This is mainly done through upgrading the existing drugs and undergoing substantial clinical trials to explore their complete potential with funding activities. For instance, in March 2025, Tempero Bio, Inc. secured USD 70 million in Series B financing for advancing TMP-301 into Phase 2 trials for substance use disorders such as alcohol and cocaine use disorders, which was led by Aditum Bio, Khosla Ventures, and others. These investments, in addition to other strategic collaborations, are projected to influence significant market activities, maintaining healthy competition between the global players.

Some of the prominent players in the alcohol use disorder treatment market are:

Alkermes Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Teva Pharmaceutical Industries Ltd.
BioCorRx, Inc
Adial Pharmaceuticals
ADDEX THERAPEUTICS
Kinnov Therapeutics
Opiant Pharmaceuticals
Ethypharm
Omeros Corporation
Montisera Ltd.
Altimmune, Inc.,
BioCorRx Inc
Amygdala Neurosciences, Inc
Clearmind Medicine Inc.
DURECT Corporation
Adial Pharmaceuticals, Inc
Pear Therapeutics
Tempero Bio, Inc.

Browse key industry insights with market data tables & charts from the report:

Alcohol Use Disorder Treatment Market Size Report 2037

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the alcohol use disorder treatment market was over USD 742 million.

The market size for the alcohol use disorder treatment market is projected to reach USD 1.6 billion by the end of 2037, expanding at a CAGR of 6.4% during the forecast period, i.e., between 2025-2037.

The major players in the market are Teva Pharmaceutical Industries Ltd., BioCorRx, Inc, Adial Pharmaceuticals, ADDEX Therapeutics, Kinnov Therapeutics, Opiant Pharmaceuticals, and others.

In terms of the treatment type segment, the multidisciplinary treatment segment is anticipated to garner the largest market share of 52% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 46% by the end of 2037 and provide more business opportunities in the future.